Monday, October 6, 2025

Latest

Mind Medicine Pays JR Rahn $6.7 Million In Shares To Leave Leadership Roles

It seems that after selling $24.7 million in company stock, JR Rahn is looking to step down from Mind Medicine (NEO: MMED) (NASDAQ: MNMD). The firm this morning announced that Rahn will be stepping down from his role as both CEO and director of the company in which in co-founded. The best part, is he will be paid to do so.

As part of the agreement for Rahn to step down from his role, the company has notably agreed to issue him 1.5 million subordinate voting shares. Effectively, Rahn will see a pay day equivalent to $6.68 million just for leaving his role as an executive of the company.

Taking Rahn’s place as CEO of the company will be that of Robert Barrow, the firms chief development officer, effective immediately. The company has also commence a “comprehensive search for a chief executive officer,” for which Barrow is to be a candidate, with Rahn advising the firm on its transition.

The transition reportedly will “enable the company to pursue aggressively its clinical development programs and development of its companion innovative digital technologies.” Commenting on his transition, Rahn stated, “Our work to date and ability to raise capital has taken us leaps and bounds closer to that vision. This chief executive officer transition is a natural progression for MindMed as the Company heads into later stage clinical trials.”

Mind Medicine last traded at $4.45 on the Neo.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched...

Wednesday, May 5, 2021, 09:44:00 AM

MindMed Closes $34.5 Million Financing, Cash Reserves Said To Be At $85 Million

Mind Medicine (NEO: MMED) has completed its previously announced bought deal private placement, raising gross...

Friday, December 11, 2020, 09:15:15 AM

MindMed Adds MDMA To R&D Pipeline

Mind Medicine, also known as MindMed (NEO: MMED) this morning announced that it is branching...

Wednesday, May 27, 2020, 09:00:04 AM

Mind Medicine CFO Quits Ahead Of Release Of 2021 Financial Results

It’s always a positive sign when a chief financial officer resigns the last business day...

Monday, March 28, 2022, 06:45:00 AM

Mindmed: Canaccord Calls Financing “Puzzling And Unusual”

This past week Mind Medicine Inc. (NEO: MMED) announced that they would be doing a...

Saturday, October 1, 2022, 01:04:00 PM